These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20425085)

  • 1. Glucocorticoid-induced osteoporosis: management update.
    Adler RA
    Curr Osteoporos Rep; 2010 Mar; 8(1):10-4. PubMed ID: 20425085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
    Kaneko K; Kawai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data from extension trials: denosumab and zoledronic acid.
    Dore RK
    Curr Osteoporos Rep; 2012 Mar; 10(1):16-21. PubMed ID: 22086442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for glucocorticoid-induced osteoporosis.
    Chiodini I; Merlotti D; Falchetti A; Gennari L
    Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm G
    Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucocorticoid-induced osteoporosis and osteonecrosis.
    Weinstein RS
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):595-611. PubMed ID: 22877431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
    Suzuki Y; Sato S
    Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases.
    Kim JW; Jung JY; Kim HA; Son H; Suh CH
    Postgrad Med J; 2024 Apr; 100(1183):334-341. PubMed ID: 38297995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of glucocorticoid-induced osteoporosis.
    Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
    Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.
    Silverman SL
    Curr Osteoporos Rep; 2009 Sep; 7(3):91-5. PubMed ID: 19723467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
    Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
    Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis.
    Etani Y; Ebina K; Hirao M; Kitaguchi K; Kashii M; Ishimoto T; Nakano T; Okamura G; Miyama A; Takami K; Goshima A; Kanamoto T; Nakata K; Yoshikawa H
    Bone; 2020 Oct; 139():115525. PubMed ID: 32645445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longer-lasting osteoporosis drugs sought.
    Kuehn BM
    JAMA; 2005 May; 293(20):2458. PubMed ID: 15914731
    [No Abstract]   [Full Text] [Related]  

  • 17. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is new in the treatment of steroid-induced osteoporosis?
    Liu RH; Werth VP
    Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological management of osteoporosis.
    Riek AE; Towler DA
    Mo Med; 2011; 108(2):118-23. PubMed ID: 21568234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug-induced osteoporosis].
    Tanaka Y
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():394-8. PubMed ID: 18074570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.